China Accepts Boan Biotechnology's Biologics License Application for Type 2 Diabetes Drug
China Accepts Boan Biotechnology's Biologics License Application for Type 2 Diabetes Drug
中國接受博安生物科技的2型糖尿病藥物生物製劑許可申請
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊